Quality Indicators in Laboratory Medicine: Key Metrics for Performance Monitoring

Laboratory quality indicators are quantifiable measures used to monitor and evaluate performance across the total testing process, spanning pre-analytical, analytical, and post-analytical phases. For laboratory students, technicians, researchers, and diagnostic professionals, understanding these metrics is essential for identifying errors, guiding improvement initiatives, and ensuring patient safety. This article defines key quality indicators for each phase of laboratory testing and provides practical guidance on tracking, interpreting, and acting on the data they generate.

The Total Testing Process and the Role of Quality Indicators

The total testing process encompasses every step from test ordering to result interpretation and clinical action. Errors can occur at any point in this continuum, and their consequences range from delayed diagnosis to inappropriate patient management. Quality indicators serve as the measurement tools that make these errors visible and quantifiable.

Clinical laboratory test results influence a substantial portion of essential clinical decisions, including hospital admissions, medication prescribing, and patient discharges. When errors compromise the accuracy or reliability of results, clinical decisions are directly affected. This places quality monitoring at the center of laboratory operations instead of at the periphery.

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group on Laboratory Errors and Patient Safety has developed a Model of Quality Indicators to standardize how laboratories measure performance. A 2025 recommendation from this group identified six essential quality indicators that are globally applicable and focused on patient safety and clinical outcomes. These include the rate of misidentified requests and samples, the rate of sample rejections, the rate of hemolysis detected, the rate of unacceptable results in external quality assessment, the turnaround time of cardiac troponin at the 90th percentile for the emergency room, and the rate of incorrect laboratory reports. The selection prioritized the probability of patient harm, ease of detection, and feasibility of data collection within national contexts.

The World Health Organization Laboratory Quality Management System Handbook provides foundational guidance on establishing quality systems in laboratories. The handbook addresses the components of a quality management system, including organization, personnel, equipment, purchasing and inventory, process control, information management, documents and records, occurrence management, assessment, process improvement, customer service, and facilities and safety. Quality indicators are integral to the process improvement and assessment components of this framework.

Pre-Analytical Quality Indicators

Pre-analytical errors consistently represent the largest source of laboratory errors across the total testing process. Studies from diverse settings confirm this pattern. A study of a stat laboratory in 2014 found that pre-analytical errors accounted for 0.8% of all samples received in a year, with hemolyzed samples and clotted samples being the most common error types. A 2025 study in Ethiopia reported that pre-analytical errors constituted 63.6% of all errors across the total testing process. A 2014 study in a cancer center laboratory in India found that pre-analytical and post-analytical errors together constituted more than 90% of all errors, with pre-analytical errors being most common in both years of the study.

Sample Rejection Rate

The sample rejection rate is one of the most fundamental pre-analytical quality indicators. It measures the proportion of samples that cannot be processed due to quality issues. Common reasons for rejection include clotting, hemolysis, insufficient volume, incorrect container, misidentification, and transport-related degradation.

A 2026 study across a regional medical laboratory network in China analyzed 7,437,716 biological samples and found a rejection rate of 0.057% based on four quality indicator criteria. Clotted samples accounted for 43.37% of total rejections, and incorrect sample volume accounted for 24.50%. Notably, inadequate mixing was identified as the cause of 62.25% of clotting incidents. This finding points to a specific, addressable training and procedure issue at the collection site.

A 2026 study in a tertiary care hospital evaluated 1,885,043 samples and found a consistent sample rejection rate of 0.14% before and after a laboratory audit. Clotted samples were the primary reason for rejection, accounting for 47.5% of total rejections, followed by incorrect vacuum vial or barcode mismatch.

Hemolysis Rate

Hemolysis is a leading cause of sample rejection, particularly in biochemistry testing. In the stat laboratory study, hemolyzed samples accounted for 46.4% of all pre-analytical errors. Hemolysis can be detected either by automated hemolysis index or by visual inspection, and the IFCC essential quality indicator panel includes both detection methods.

The hemolysis rate is a useful indicator because it reflects multiple aspects of the pre-analytical process, including phlebotomy technique, tourniquet time, sample transport, and centrifugation practices. Tracking hemolysis rates by collection site, phlebotomist, or ward can identify specific areas requiring intervention.

Sample Misidentification Rate

Misidentified requests and misidentified samples are among the most dangerous pre-analytical errors because they can lead to results being reported for the wrong patient. The IFCC essential quality indicator panel includes the rate of misidentified requests and the rate of misidentified samples as separate indicators. In the stat laboratory study, requests with errors in patient identification accounted for 0.7% of pre-analytical errors.

Clotted Sample Rate

Clotting is a frequent cause of rejection in hematology samples. In the stat laboratory study, clotted samples accounted for 43.2% of pre-analytical errors. The 2026 regional network study found that inadequate mixing was the primary cause of clotting, which suggests that collector training on proper tube inversion is a high-yield improvement target.

Insufficient Sample Volume

Insufficient sample volume prevents complete testing or requires redraws. The 2026 regional network study found that primary sample volume issues included insufficient urine volume and empty stool containers. This indicator is straightforward to track and often reveals collection training gaps.

Inappropriate Sample Container

Samples collected in the wrong container type can compromise test results due to inappropriate anticoagulants or additives. The stat laboratory study found that samples collected in tubes with inappropriate anticoagulant accounted for 0.3% of pre-analytical errors. The 2026 regional network study found that nasopharyngeal swabs, urine, and secretion samples collectively represented over 50% of incorrect container incidents, and sputum incorrectly collected as stool or urine was a common sample type error.

Transport and Storage Related Indicators

Sample transport and storage conditions affect specimen integrity. A 2026 study on coagulation testing found that storage at -80 degrees Celsius or in liquid nitrogen preserved prothrombin time and activated partial thromboplastin time values, whereas storage at -20 degrees Celsius caused variable prolongation. This finding demonstrates that storage conditions are not neutral variables and must be monitored as part of pre-analytical quality.

For resource-limited settings, pre-analytical errors are amplified by inadequate infrastructure, unreliable transport systems, workforce shortages, and weak quality management systems. A 2026 review identified hemolysis, specimen misidentification, clotting, insufficient sample volume, and transport-related degradation as the predominant causes of pre-analytical failure in these contexts. The review emphasized the need for adaptive protocols, human-centered quality interventions, and appropriate technologies.

Analytical Quality Indicators

Analytical quality indicators focus on the performance of the measurement procedures themselves. These indicators monitor the accuracy, precision, and reliability of test results produced by the laboratory.

Internal Quality Control Performance

Internal quality control involves analyzing control materials with known values alongside patient samples to verify that the measurement procedure is performing within acceptable limits. Key indicators include the number of internal quality control outliers and the frequency of control failures.

A 2024 study in a clinical bacteriology laboratory tracked internal quality control outliers as one of its analytical phase quality indicators. The laboratory recorded 25 internal quality control outliers from January 2019 through March 2021. Tracking outliers by test, instrument, and operator can reveal patterns that point to specific causes.

External Quality Assessment Performance

External quality assessment, also known as proficiency testing, involves analyzing samples provided by an external organization and comparing results with those of other laboratories. The rate of unacceptable results in external quality assessment is one of the six essential quality indicators recommended by the IFCC Working Group.

A 2024 study in a clinical bacteriology laboratory reported an average external quality assurance scheme performance score of 97.44% from January 2018 to March 2021. A 2026 study analyzing six consecutive external quality assessment cycles for 19 routine biochemical analytes found that most analytes demonstrated acceptable Z-scores and stable assigned values. However, notable exceptions included ALT with a Z-score of 24.3 in February, AST with a Z-score of 4.15 in January, ALP with a Z-score of 3.21 in May, and HDL with Z-scores above 2.0 in December, January, and May. These findings suggested potential issues related to methodology, calibration, or instrumentation. Persistent inter-laboratory variability was observed for amylase, ALT, and ALP.

The sigma value for tests covered by interlaboratory comparison is another analytical quality indicator. A 2026 study applying sigma metrics to 15 quality indicators found that the average sigma value for tests covered by interlaboratory comparison was the lowest among all indicators at 1.01, indicating substantial room for improvement in this area.

Lot-to-Lot Verification

Lot-to-lot verification is an integral component for monitoring the long-term stability of a measurement procedure. When a laboratory receives a new reagent lot, it must verify that the new lot performs comparably to the previous lot before putting it into routine use. A 2023 review noted that this practice is challenged by resource requirements and uncertainty surrounding experimental design and statistical analysis. Collaborative verification efforts and patient-based monitoring can improve identification of performance differences. When lot-to-lot verification fails, appropriate follow-up actions are required, and these must balance potential disruptions to clinical services. The review emphasized that manufacturers need to increase transparency surrounding release criteria and work with laboratory professionals to ensure acceptable reagent lots are released.

Method Validation and Verification

Method validation is the process of demonstrating that a measurement procedure is suitable for its intended purpose. The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance provides recommendations for validating bioanalytical methods used in nonclinical and clinical studies. The guidance addresses key parameters including selectivity, accuracy, precision, recovery, calibration curves, and stability.

The National Center for Advancing Translational Sciences Assay Guidance Manual provides comprehensive information on assay development and validation. The manual covers topics such as assay design, reagent preparation, quality control, and data analysis. For laboratories developing their own tests, the Assay Guidance Manual serves as a practical reference for establishing assay performance characteristics.

Laboratory developed tests require particular attention to validation. A 2023 article discussed how ISO 15189 can serve as a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house use under the European In-Vitro Diagnostics Regulation. The article noted that laboratory developed tests serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments. The regulatory framework should reduce the burden on the health care system by making diligent use of existing frameworks.

Molecular Assay Specific Considerations

Molecular assays have unique analytical quality considerations. A 1997 article on multiplex PCR identified critical parameters for successful assays, including the relative concentrations of primers at various loci, the concentration of the PCR buffer, the cycling temperatures, and the balance between magnesium chloride and deoxynucleotide concentrations. These parameters must be optimized and controlled to ensure reliable results.

A 2021 article on SARS-CoV-2 nucleic acid detection described laboratory management and quality control practices established during the pandemic. The article emphasized the importance of maintaining standard and accurate laboratory operations for nucleic acid testing, including cross-department personnel management and key points of personal protection and quality control in the testing process. The article also reported on differences in detection and compatibility between different brand kits, highlighting the need for careful kit selection and verification.

Post-Analytical Quality Indicators

Post-analytical quality indicators monitor the processes that occur after testing is complete, including result reporting, interpretation, and communication to clinicians. A 2025 study in Guangdong Province, China, found that post-analytical phase quality indicators achieved the best performance compared with pre-analytical and analytical indicators from 2020 to 2023. However, post-analytical errors still represent a substantial portion of total errors. The 2025 Ethiopian study found that post-analytical errors accounted for 34.8% of all errors across the total testing process.

Turnaround Time

Turnaround time is a critical post-analytical indicator because delayed results can affect clinical decision-making. The IFCC essential quality indicator panel includes the turnaround time of cardiac troponin at the 90th percentile for the emergency room as one of six essential indicators. This metric captures both the timeliness and the reliability of reporting for a time-sensitive test.

A 2026 study in a tertiary care hospital found that the number of reports surpassing the turnaround time measure decreased from 5.61% in the pre-audit period to 5.01% in the post-audit period. This improvement was statistically significant and demonstrated that audit-driven quality improvement can produce measurable gains in turnaround time performance.

Critical Values Notification

Critical values are results that indicate a life-threatening condition requiring immediate clinical action. The timely notification of critical values is a key post-analytical quality indicator. A 2026 study applying sigma metrics found that critical values notification and timely critical values notification were both 100% every year from 2019 through 2024. This finding demonstrates that high performance on this indicator is achievable and sustainable.

Incorrect Laboratory Reports

The rate of incorrect laboratory reports is one of the six essential quality indicators recommended by the IFCC Working Group. This indicator captures errors in result transcription, report generation, and result interpretation. A 2026 study in a genetics laboratory found that manual report generation processes were time-consuming and prone to errors. The laboratory developed a rule-based tool that automated quality management report generation by directly extracting and processing electronic laboratory records from the health information system. Implementation of this tool reduced report preparation time by 90% and eliminated discrepancies compared with manual reports.

Result Verification and Release

The process of verifying results before release is a post-analytical quality control step. This includes reviewing quality control data, checking for delta changes from previous results, and confirming that results are consistent with clinical information when available. The Croatian Society of Medical Biochemistry and Laboratory Medicine has published national recommendations for quality indicators of the post-analytical phase, providing guidance on which indicators to track and how to interpret them.

At a Glance: Essential Quality Indicators by Testing Phase

The following table summarizes key quality indicators for each phase of the total testing process, along with the typical data source and the primary purpose of each indicator.

Implementing a Quality Indicator Program

Implementing a quality indicator program requires a structured approach that integrates data collection, analysis, and improvement actions into routine laboratory operations.

Step 1: Select Indicators

Begin with a limited set of indicators that are feasible to collect and relevant to your laboratory's scope. The IFCC essential quality indicator panel provides a starting point that covers the total testing process. Laboratories with more mature quality systems can expand to additional indicators based on their specific testing menu and identified risk areas.

Step 2: Define Data Collection Methods

Determine how data will be collected for each indicator. Laboratory information systems can automate data collection for many indicators, including sample rejection rates, turnaround times, and critical values notification. Other indicators may require manual data collection, such as visual inspection for hemolysis or review of report correction records.

A 2026 study described the development of an integrated informatics platform to harmonize sample collection quality indicator monitoring across a regional medical laboratory network. The platform included a standardized dictionary of rejection types and reasons configured into the laboratory information system sample rejection menu. The web-based quality indicator management system provided automated data collection, quality indicator calculation, visual analytics, and a corrective action implementation module. This example demonstrates how informatics infrastructure can support consistent and reliable quality indicator monitoring.

Step 3: Establish Reporting Frequency

Determine how often each indicator will be calculated and reviewed. Some indicators, such as critical values notification, may be monitored continuously or daily. Others, such as external quality assessment performance, are naturally tied to the frequency of proficiency testing events. Monthly reporting is common for most quality indicators and allows for trend detection without excessive data collection burden.

Step 4: Set Quality Specifications

Quality specifications define the acceptable performance level for each indicator. These can be based on published benchmarks, regulatory requirements, or local historical performance. The IFCC Working Group has published quality specifications for many indicators, and national programs may provide additional benchmarks.

A 2025 study in Guangdong Province, China, defined optimum, desirable, and minimum quality specifications based on the percentiles of quality indicator results from 335 laboratories. The study found that the quality specifications for 15 quality indicators in Guangdong Province in 2023 were stricter or roughly equivalent to those published by the IFCC Working Group, except for the percentage of intra-laboratory turnaround time for emergency potassium tests. This example illustrates how regional data can be used to establish locally appropriate quality specifications.

Step 5: Analyze and Interpret Data

Quality indicator data should be analyzed for trends and compared with quality specifications. Statistical process control charts, such as P-control charts, are useful for monitoring rates over time and detecting special cause variation. A 2026 study in a regional medical laboratory network used P-control charts for continuous rejection rate monitoring.

Sigma metrics provide another framework for interpreting quality indicator data. Sigma values are calculated from the rate of errors, with higher sigma values indicating better performance. A 2026 study applying sigma metrics to 15 quality indicators found that the average sigma value for incorrect sample type was the highest at 5.73, while the average sigma value for tests covered by interlaboratory comparison was the lowest at 1.01. The study also applied the TOPSIS method to comprehensively rank laboratory quality across different years, specialties, and specimen types.

Step 6: Implement Improvement Actions

Quality indicators are only valuable when they lead to improvement. When an indicator exceeds its quality specification or shows a deteriorating trend, the laboratory should investigate the root cause and implement corrective actions. A 2025 study described a quality improvement initiative that compared hospital laboratory data with national and international quality specifications to identify performance gaps. Based on this analysis, a series of data-driven continuous improvement projects were implemented, and statistically significant improvements were observed in seven indicators. The study concluded that effective communication and interdisciplinary collaboration are essential for reducing errors and enhancing laboratory performance.

Step 7: Review and Revise the Program

Quality indicator programs should be reviewed periodically to ensure that the selected indicators remain relevant and that data collection methods remain efficient. The 2024 study in a clinical bacteriology laboratory described how the laboratory started with one quality indicator for each phase in 2018 and added indicators over time. In 2021, the acceptable limit for one pre-analytical quality indicator was reduced from 2% to 1%, reflecting improved performance and a commitment to continuous improvement.

Records and Measurements

Accurate records are the foundation of any quality indicator program. The following records should be maintained for each quality indicator:

The World Health Organization Laboratory Quality Management System Handbook emphasizes the importance of document and record control as a component of the quality management system. Records must be legible, identifiable, and retrievable, and they must be retained for a defined period.

Common Failure Patterns in Quality Indicator Programs

Several common failure patterns can undermine the effectiveness of quality indicator programs. Recognizing these patterns is the first step in avoiding them.

Incomplete Data Collection

Quality indicators are only as reliable as the data behind them. When data collection relies on manual processes, errors and omissions are common. A 2026 study in a genetics laboratory found that manual report generation processes were time-consuming and prone to errors. The study developed a rule-based tool that automated report generation by directly extracting and processing electronic laboratory records, reducing report preparation time by 90% and eliminating discrepancies.

Focusing on Easy Indicators instead of Important Ones

Laboratories may be tempted to track indicators that are easy to measure instead of those that matter most for patient safety. The IFCC essential quality indicator panel was specifically designed to prioritize indicators based on the probability of patient harm, ease of detection, and feasibility of data collection. Laboratories should ensure that their indicator set includes the essential indicators even if they require more effort to collect.

Lack of Integration with Improvement Actions

Quality indicator data that is collected but not acted upon provides no value. The 2025 quality improvement study demonstrated that measurable improvements were achieved when indicator evaluation was integrated with adverse event analysis and corrective actions. Laboratories should establish a clear process for reviewing indicator data, identifying root causes, implementing corrective actions, and verifying the effectiveness of those actions.

Inconsistent Definitions

Quality indicators are only comparable across time and between laboratories when definitions are consistent. The 2026 regional network study addressed this by configuring a standardized dictionary of rejection types and reasons into the laboratory information system. Without standardized definitions, apparent changes in indicator values may reflect changes in data collection instead of changes in performance.

Insufficient Training

Quality indicator programs require staff at all levels to understand the purpose of the indicators and their role in data collection. The 2014 cancer center study concluded that further improvements in laboratory services are contingent on adequate training and interdepartmental communication and cooperation. Training should cover also how to collect data but also why the data matters.

Limitations of Quality Indicators

Quality indicators have inherent limitations that must be understood for proper interpretation.

Indicators Measure Processes, Not Outcomes

Most quality indicators measure process performance, such as the rate of sample rejection or the timeliness of reporting. They do not directly measure patient outcomes. The assumption is that better process performance leads to better outcomes, but this link is not always direct or immediate.

Data Quality Depends on Detection Methods

Some errors are easier to detect than others. For example, hemolysis can be detected by automated hemolysis index or visual inspection, but the sensitivity of these methods differs. A 2020 article on mitophagy probes noted that uncertainties in the operational principles of conventional probes made the specificity and quantitativeness of their readouts disputable. While this example is from a research context, the principle applies to laboratory quality indicators: the measurement method affects what is measured.

Benchmark Comparisons May Not Be Appropriate

Comparing quality indicator values with published benchmarks requires caution. Benchmarks may come from laboratories with different testing menus, patient populations, or resource levels. The 2025 Guangdong Province study found that quality specifications for some indicators were stricter than IFCC specifications, while the 2025 quality improvement study found that laboratory performance was ranked relatively low at the national level but favorably at the international level. These findings illustrate that the choice of benchmark affects the interpretation of performance.

Low Event Rates Create Statistical Challenges

Some quality indicators have very low event rates, making it difficult to detect meaningful changes. For example, a sample rejection rate of 0.057% in the 2026 regional network study means that only 4,208 rejections occurred among 7,437,716 samples. Detecting a small but real change in such a rate requires large sample sizes and careful statistical analysis.

Resource Constraints

Quality indicator programs require resources for data collection, analysis, and improvement actions. In resource-limited settings, these constraints are particularly acute. The 2026 review on pre-analytical quality in resource-limited settings emphasized the need for context-appropriate interventions and appropriate technologies that are feasible in these environments.

Safety and Regulatory Context

Quality indicator programs operate within a broader safety and regulatory framework. The World Health Organization Laboratory Biosafety Manual provides guidance on biosafety practices for laboratories handling infectious materials. The manual addresses risk assessment, facility design, equipment, and operational practices that protect laboratory workers and the environment.

The International Organization for Standardization standard ISO 15189 specifies requirements for quality and competence in medical laboratories. The 2023 article on laboratory developed tests discussed how ISO 15189 can serve as a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house use. The 2014 cancer center study followed ISO 15189:2007 guidelines to identify noncompliant elements of laboratory processes.

The European In-Vitro Diagnostics Regulation regulates the design, manufacture, and putting into use of diagnostic devices, but not medical services using these devices. In the absence of suitable commercial devices, laboratories can resort to laboratory developed tests for in-house use, subject to documentary obligations and performance and safety specifications. The 2023 article noted that unintended collateral damage of the regulation could include loss of non-profitable niche applications, increases in costs and wasted resources, and migration of innovative research to more cost-efficient environments.

For infectious disease testing, diagnostic algorithms may require specific approaches. A 2016 update of the European Society of Clinical Microbiology and Infectious Diseases guidance for diagnosing Clostridium difficile infection found that no single commercial test can be used as a stand-alone test due to inadequate positive predictive values at low disease prevalence. The guidance recommended a two-step algorithm, with samples without free toxin detected by toxin enzyme immunoassay but with positive glutamate dehydrogenase enzyme immunoassay, nucleic acid amplification test, or toxigenic culture results requiring clinical evaluation to discern infection from asymptomatic carriage. This example illustrates how quality considerations extend beyond analytical performance to test selection and algorithm design.

Professional Escalation Criteria

Laboratory professionals should know when to escalate quality issues beyond the laboratory. The following situations warrant escalation to laboratory management, hospital administration, or external bodies.

Persistent Failure to Meet Quality Specifications

When a quality indicator consistently exceeds its quality specification despite corrective actions, the issue should be escalated. For example, if external quality assessment results show persistent unacceptable performance for a specific analyte across multiple cycles, this may indicate a systemic problem with methodology, calibration, or instrumentation that requires manufacturer involvement or method change.

Reagent Lot Failures

When lot-to-lot verification fails and the laboratory cannot identify an acceptable alternative, the issue should be escalated to the manufacturer. The 2023 review on lot-to-lot variation noted that manufacturers need to increase transparency surrounding release criteria and work closer with laboratory professionals to ensure acceptable reagent lots are released to end users.

Safety Concerns

Any quality issue that poses a risk to laboratory workers, patients, or the environment should be escalated immediately. The World Health Organization Laboratory Biosafety Manual provides guidance on risk assessment and the reporting of incidents and accidents.

Regulatory Non-Compliance

When a quality issue indicates potential non-compliance with regulatory requirements, such as ISO 15189 or national regulations, the issue should be escalated to the appropriate regulatory body. The 2023 article on laboratory developed tests discussed the responsibilities of national legislators and competent authorities in the context of the European In-Vitro Diagnostics Regulation.

Critical Value Notification Failures

Failures in critical value notification that result in delayed clinical action should be escalated through the hospital's patient safety reporting system. These events represent direct threats to patient safety and require immediate investigation.

Frequently Asked Questions

What is the difference between a quality indicator and a quality control measure?

A quality indicator is a metric used to monitor performance across the total testing process, such as the sample rejection rate or turnaround time. A quality control measure is a specific procedure used to verify that a measurement procedure is performing within acceptable limits, such as analyzing control materials with known values alongside patient samples. Quality control measures generate data that feed into some quality indicators, such as the internal quality control outlier rate, but quality indicators encompass a broader range of process and outcome measures.

How many quality indicators should a laboratory track?

The number of quality indicators should be matched to the laboratory's scope, resources, and quality system maturity. The IFCC Working Group on Laboratory Errors and Patient Safety has recommended a panel of six essential quality indicators that cover the total testing process and are feasible to implement in most settings. Laboratories with more mature quality systems can expand to additional indicators based on their specific testing menu and identified risk areas. Starting with a limited set of well-defined indicators is preferable to tracking many indicators with incomplete or unreliable data.

How often should quality indicators be calculated and reviewed?

The reporting frequency depends on the indicator and the volume of data available. Some indicators, such as critical values notification, may be monitored continuously or daily. Others, such as external quality assessment performance, are naturally tied to the frequency of proficiency testing events. Monthly reporting is common for most quality indicators and allows for trend detection without excessive data collection burden. Low event rate indicators may require quarterly or longer reporting periods to accumulate sufficient data for meaningful analysis.

What is a sigma value and how is it used in quality indicator interpretation?

A sigma value is a metric that expresses the error rate of a process in terms of standard deviations from the mean. Higher sigma values indicate better performance, with six sigma representing a very low error rate. Sigma values are calculated from the rate of errors using a specific formula. A 2026 study applying sigma metrics to 15 quality indicators found that the average sigma value for incorrect sample type was the highest at 5.73, while the average sigma value for tests covered by interlaboratory comparison was the lowest at 1.01. Sigma values can be used to compare performance across different indicators and to prioritize improvement efforts.

How should a laboratory respond when a quality indicator exceeds its quality specification?

When a quality indicator exceeds its quality specification, the laboratory should investigate the root cause, implement corrective actions, and verify the effectiveness of those actions. The investigation should include a review of the relevant records, observation of the processes involved, and discussion with the staff responsible for those processes. Corrective actions should address the root cause instead of the symptoms. The 2025 quality improvement study demonstrated that measurable improvements were achieved when indicator evaluation was integrated with adverse event analysis and corrective actions.

What are the most common pre-analytical errors that quality indicators detect?

The most common pre-analytical errors detected by quality indicators include hemolysis, clotting, insufficient sample volume, incorrect container, misidentification, and transport-related degradation. A 2014 stat laboratory study found that hemolyzed samples accounted for 46.4% of pre-analytical errors and clotted samples accounted for 43.2%. A 2026 regional network study found that clotted samples accounted for 43.37% of total rejections and incorrect sample volume accounted for 24.50%. Inadequate mixing was identified as the cause of 62.25% of clotting incidents.

How can laboratories in resource-limited settings implement quality indicator programs?

Laboratories in resource-limited settings can implement quality indicator programs by starting with a limited set of feasible indicators, using simple data collection methods, and focusing on the most common error types. A 2026 review on pre-analytical quality in resource-limited settings emphasized the need for adaptive protocols, human-centered quality interventions, and appropriate technologies. The review identified hemolysis, specimen misidentification, clotting, insufficient sample volume, and transport-related degradation as the predominant causes of pre-analytical failure in these contexts, amplified by systemic weaknesses.

What is the role of external quality assessment in monitoring analytical quality?

External quality assessment, also known as proficiency testing, involves analyzing samples provided by an external organization and comparing results with those of other laboratories. The rate of unacceptable results in external quality assessment is one of the six essential quality indicators recommended by the IFCC Working Group. External quality assessment verifies inter-laboratory comparability and can detect method-specific or instrument-specific problems. A 2026 study analyzing six consecutive external quality assessment cycles found that most analytes demonstrated acceptable Z-scores and stable assigned values, but persistent inter-laboratory variability was observed for amylase, ALT, and ALP.

Related Diagnostic Guides

• qPCR Amplification Curves: How to Read and Interpret Them
• Quality Control Analysis: Methods for Monitoring Lab Performance
• Antimicrobial Susceptibility Testing and MIC Interpretation in Veterinary Medicine
• Chemical Indicators for Sterilization Monitoring: Types, Placement, and Interpretation
• Quality Control in the Microbiology Laboratory: Key Practices for Reliable Results

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Multiplex PCR: critical parameters and step-by-step protocol.. BioTechniques, 1997.
• Visualizing and Modulating Mitophagy for Therapeutic Studies of Neurodegeneration.. Cell, 2020.
• Lot-to-lot variation and verification.. Clinical chemistry and laboratory medicine, 2023.
• Quality indicators in the preanalytical phase of testing in a stat laboratory.. Laboratory medicine, 2014.
• European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2016.
• Evaluation of quality indicators in a laboratory supporting tertiary cancer care facilities in India.. Laboratory medicine, 2014.
• ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation.. Clinical chemistry and laboratory medicine, 2023.
• Laboratory Management and Quality Control Practice of SARS-CoV-2 Nucleic Acid Detection.. Laboratory medicine, 2021.
• Best practices in sample management &amp, pre-analytical quality control: overcoming challenges in resource-limited laboratory settings.. 2026.
• Pre-analytical storage and reagent-dependent sensitivity as sources of variability in prothrombin time and activated partial thromboplastin time measurements.. 2026.
• Evaluation of Pre-Analytical, Analytical, and Post-Analytical Quality Indicators Before and After Laboratory Audit in a Tertiary Care Hospital. 2026.
• Development and validation of a rule-based tool for quality management reporting in a genetics laboratory.. 2026.
• Harmonizing sample collection quality indicator monitoring via an informatics platform in a regional medical laboratory network.. 2026.
• Issues in the Preanalytical Process of Specimens for Laboratory Tests in Home Healthcare Settings. 2026.
• Application of Sigma Metric and TOPSIS Method to Comprehensively Analyze 15 Quality Indicators in Clinical Laboratory from 2019 Through 2024.. Clinical Laboratory, 2026.
• Evaluating the total laboratory testing process and performance via quality indicators in clinical chemistry and hematology laboratories at Pawi General Hospital, Benishangul Gumz, Northwest Ethiopia: a prospective cross-sectional study. Discover Health Systems, 2025.
• Continual Improvement in Clinical Bacteriology Laboratory with Quality Indicators: A Retrospective Observational Study. Journal of Clinical and Diagnostic Research, 2024.
• Quality indicators in laboratory medicine: a 2020-2023 experience in a Chinese province. Clinical Chemistry and Laboratory Medicine, 2025.
• Recommendations from the IFCC Working Group on Laboratory Errors and Patient Safety for the Global Adoption of an Essential Quality Indicators Panel in Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2025.
• From assessment to action: experience from a quality improvement initiative integrating indicator evaluation and adverse event analysis in a clinical laboratory. Clinical Chemistry and Laboratory Medicine, 2025.
• "Evaluating Laboratory Quality Indicators Through External Quality Assessment Scheme (Eqas): A Focused Analysis ON Performance Trends AND Assigned Value Shifts". "Evaluating Laboratory Quality Indicators Through External Quality Assessment Scheme (Eqas): A Focused Analysis ON Performance Trends AND Assigned Value Shifts", 2025.
• Establishment of Preanalytical Quality Indicators and Current Status of Preanalytical Phase Laboratory Performance Monitoring in the Clinical Laboratories in Korea. Journal of Laboratory Medicine and Quality Assurance, 2024.
• Quality indicators in laboratory medicine: State-of-the-art, quality specifications and future strategies. Clinical Chemistry and Laboratory Medicine, 2023.
• National recommendations of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Quality indicators of the postanalytical phase. Biochemia Medica, 2026.
• Towards harmonization of quality indicators in laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2013.
• Harmonization of quality indicators in laboratory medicine. A preliminary consensus. Clinical Chemistry and Laboratory Medicine, 2014.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.